Zobrazeno 1 - 10
of 517
pro vyhledávání: '"Roland B. Walter"'
Autor:
John J. Lim, Megan Othus, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Paul Hendrie, Roland B. Walter, Elihu H. Estey, Mary-Elizabeth M. Percival
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/845027fb887844a09bcecd5251187282
Autor:
Nicholas E. Petty, Stefan Radtke, Emily Fields, Olivier Humbert, Mallory J. Llewellyn, George S. Laszlo, Haiying Zhu, Keith R. Jerome, Roland B. Walter, Hans-Peter Kiem
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 31, Iss , Pp 101121- (2023)
Current immunotherapeutic targets are often shared between neoplastic and normal hematopoietic stem and progenitor cells (HSPCs), leading to unwanted on-target, off-tumor toxicities. Deletion or modification of such targets to protect normal HSPCs is
Externí odkaz:
https://doaj.org/article/bbf076d5311d4ffc9cd892e144be7ab2
Publikováno v:
Haematologica, Vol 107, Iss 12 (2022)
Considerable progress has been made in the past several years in the scientific understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement of a conventional remission, evaluated cytomorphologically via small bone marrow
Externí odkaz:
https://doaj.org/article/337eb01baade4d8d87dfc8f07b993f9d
Autor:
Eduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, Lucas C. Zarling, Brenda M. Sandmaier, Filippo Milano, Gary Schoch, Chris Davis, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, Roland B. Walter
Publikováno v:
Haematologica, Vol 108, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/d58e180685d14f089ad142fed548839a
Autor:
Corentin Orvain, Jacob A. Wilson, Min Fang, Brenda M. Sandmaier, Eduardo Rodríguez-Arbolí, Brent L. Wood, Megan Othus, Frederick R. Appelbaum, Roland B. Walter
Publikováno v:
Haematologica, Vol 108, Iss 2 (2022)
Measurable residual disease (MRD) before hematopoietic cell transplantation (HCT) is an independent established prognostic factor in patients with acute myeloid leukemia (AML). Several methods exist to evaluate the presence of residual leukemia cells
Externí odkaz:
https://doaj.org/article/17202d83bbe0411cbe3f0805e3769126
Autor:
Raffaele Palmieri, Megan Othus, Guang-Shing Cheng, Francesco Buccisano, Giovangiacinto Paterno, Luca Maurillo, Maria Ilaria Del Principe, Giuseppe Sconocchia, Adriano Venditti, Roland B. Walter
Publikováno v:
Haematologica, Vol 107, Iss 11 (2022)
Externí odkaz:
https://doaj.org/article/c3c5c287c3784e87bcbcc54d52335c3a
Autor:
Jesse M. Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B. Walter, Brent L. Wood, Christophe Roumier, Jan Philippé, Barbara Denys, Jeffrey L. Jorgensen, Marie C. Bene, Francis Lacombe, Adriana Plesa, Monica L. Guzman, Agnieszka Wierzbowska, Anna Czyz, Lok Lam Ngai, Adrian Schwarzer, Costa Bachas, Jacqueline Cloos, Marion Subklewe, Michaela Fuering-Buske, Francesco Buccisano
Publikováno v:
HemaSphere, Vol 6, Iss 1, p e676 (2022)
Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts
Externí odkaz:
https://doaj.org/article/58aecfe07be0436ea3d70c88f7d1c3d5
Autor:
Mary-Elizabeth M. Percival, Megan Othus, Sarah Mirahsani, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Pamela S. Becker, Paul C. Hendrie, Mohamed L. Sorror, Roland B. Walter, Elihu H. Estey
Publikováno v:
Haematologica, Vol 106, Iss 8 (2020)
Few patients with cancer, including those with acute myeloid leukemia and high-grade myeloid neoplasms, participate in clinical trials. Broadening standard eligibility criteria may increase clinical trial participation. In this retrospective single-c
Externí odkaz:
https://doaj.org/article/0395b57df88646eda61744ee5d03ecfc
Autor:
Sabine Kayser, Robert K. Hills, Marlise R. Luskin, Andrew M. Brunner, Christine Terré, Jörg Westermann, Kamal Menghrajani, Carole Shaw, Maria R. Baer, Michelle A. Elliott, Alexander E. Perl, Zdeněk Ráčil, Jiri Mayer, Pavel Zak, Tomas Szotkowski, Stéphane de Botton, David Grimwade, Karin Mayer, Roland B. Walter, Alwin Krämer, Alan K. Burnett, Anthony D. Ho, Uwe Platzbecker, Christian Thiede, Gerhard Ehninger, Richard M. Stone, Christoph Röllig, Martin S. Tallman, Elihu H. Estey, Carsten Müller-Tidow, Nigel H. Russell, Richard F. Schlenk, Mark J. Levis
Publikováno v:
Haematologica, Vol 105, Iss 1 (2020)
Acute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of AML cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal with intensive chemotherapy, limited evidence s
Externí odkaz:
https://doaj.org/article/0f6f067246d842ec9f1f02982bdc9c76
Publikováno v:
Blood Advances, Vol 2, Iss 11, Pp 1356-1366 (2018)
Abstract: Mounting evidence indicates that the presence of measurable (“minimal”) residual disease (MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic detection, is a strong, independent prognostic marker of in
Externí odkaz:
https://doaj.org/article/81e8c6f5f50b463eb47cf7a96cdac38e